Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • risvutatug rezetecan (GSK5764227)

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (clinicaltrials.gov)

P1/2, N=63, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

1 day ago

Trial completion date • Trial primary completion date • Tumor mutational burden

PD-L1 IHC 22C3 pharmDx

Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • etoposide IV

DESTINY-Breast08: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (clinicaltrials.gov)

P1, N=138, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jun 2026

2 days ago

Trial completion date

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)

HER-2 expression • HER-2 underexpression • PGR positive

Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (clinicaltrials.gov)

P2, N=535, Not yet recruiting, City of Hope Medical Center

2 days ago

New P2 trial • IO biomarker

Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Krazati (adagrasib) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)

P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026

3 days ago

Trial primary completion date

cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)

IMMUNOGLYPIC: Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy (clinicaltrials.gov)

P=N/A, N=240, Recruiting, Assistance Publique - Hôpitaux de Paris | N=120 --> 240

3 days ago

Enrollment change • IO biomarker

Tecentriq (atezolizumab) • Imfinzi (durvalumab)

BRIDGE: Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (clinicaltrials.gov)

P2, N=10, Terminated, Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2026 --> Jan 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2025; Low enrolment rate

3 days ago

Trial completion date • Trial termination • Trial primary completion date

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • vinorelbine tartrate

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer (clinicaltrials.gov)

P1/2, N=208, Recruiting, IDEAYA Biosciences | N=90 --> 208

4 days ago

Enrollment change

Imfinzi (durvalumab) • IDE161

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas (clinicaltrials.gov)

P2, N=41, Not yet recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2031 --> May 2032 | Trial primary completion date: Dec 2030 --> May 2031

4 days ago

Trial completion date • Trial primary completion date

Imfinzi (durvalumab) • Koselugo (selumetinib)

NCI-2018-01581: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)

P2, N=70, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026

4 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)

HER-2 negative • PD-L1 negative

carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC)

Precision Targeted-Immunotherapy for BRAF V600E and MET-Amplified Biliary Tract Cancer: Two Case Reports. (PubMed, Oncologist)

Combining targeted therapies with immune checkpoint inhibitors showed promising results in two patients with advanced BTC driven by specific genetic mutations. Significant tumor reduction and successful surgeries suggest this approach may improve resectability and outcomes. These cases highlight the potential of personalized treatment guided by genetic profiling. Further research is needed to confirm these findings and explore broader applications for this strategy.

4 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)

BRAF V600E • BRAF V600 • MET amplification

Mekinist (trametinib) • Tafinlar (dabrafenib) • Imfinzi (durvalumab) • Tepmetko (tepotinib)